Relacorilant PDUFA Date (Corcept Therapeutics)
FDA PDUFA decision date for Relacorilant is December 30, 2025. Developed by Corcept Therapeutics. Indication: Cushing's syndrome. Current status: CRL.
Indication
Cushing's syndrome
Regulatory details
- Company: Corcept Therapeutics
- Therapeutic area: Rare Disease / Endocrine
- Application type: NDA
- Review type: Standard
- PDUFA date: 2025-12-30
- Outcome: CRL